[Wyeth Logo]                                            N E W S  R E L E A S E




IMMEDIATE RELEASE


Media Contacts:                             Investor Contact:
Douglas Petkus                              Justin Victoria
Wyeth Pharmaceuticals                       Wyeth
(484) 865-5140                              (973) 660-5340

Natalie de Vane
Wyeth Pharmaceuticals
(484) 865-5139



                          Wyeth Confirms Discussions on
                     Resolution of Downstream Opt-Out Claims

     Madison, N.J., January 18, 2005 -- Wyeth (NYSE: WYE) confirms that it has
been engaged in discussions with plaintiffs' attorneys representing a number of
individuals who have opted out of the National Diet Drug Settlement on a
proposed process for settling downstream opt-out cases. The proposed process
provides a methodology for valuing different categories of claims, and also
provides a structure for individualized negotiations between Wyeth and lawyers
representing diet drug claimants. The lawyers who have been in discussions with
Wyeth would seek to obtain commitments to participate in the proposed settlement
process from other law firms representing opt-out claimants. To facilitate the
process, the parties have filed a motion with the U.S. District Court for the
Eastern District of Pennsylvania seeking a stay in proceedings in certain
pending diet drug cases.

     Wyeth's agreement to go forward with this proposal will depend upon, among
other things, the overall level of participation in the process.

     "This is a promising development, but many complex issues remain to be
resolved," says Lawrence V. Stein, General Counsel for Wyeth. "Wyeth will
continue to defend itself in the ongoing litigation until final settlements are
reached."

     This motion follows, and is unrelated to, last week's announcement of
Wyeth's support for the 7th Amendment to the National Diet Drug Settlement that
created a new claims processing structure for the least serious but most
numerous claims in the settlement.

     Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology
products and nonprescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth Pharmaceuticals,
Wyeth Consumer Healthcare and Fort Dodge Animal Health.

     The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks associated
with the inherent uncertainty of the timing and success of pharmaceutical
research, product development, manufacturing, commercialization, economic
conditions including interest and currency exchange rate fluctuations, changes
in generally accepted accounting principles, the impact of competitive or
generic products, trade buying patterns, wars or terrorist acts, product
liability and other types of lawsuits, the impact of legislation and regulatory
compliance and obtaining reimbursement, favorable drug pricing, access and other
approvals, environmental liabilities, and patent, and other risks and
uncertainties, including those detailed from time to time in the Company's
periodic reports, including current reports on Form 8-K, quarterly reports on
Form 10-Q and the annual report on Form 10-K, filed with the Securities and
Exchange Commission. Actual results may vary materially from the forward-looking
statements. The Company assumes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
events or otherwise.

                                     ######